25 results for “Disease Progression”. Showing 25 of 39,449.
Donor‐Specific Modeling of Alzheimer's Disease Progression via Cell‐Type‐Aware Single‐Cell Representations
disease (AD) progression often rely on aggregated data across cell
The natural history of degenerative ataxia: a retrospective study in 466 patients.
disease progression we defined the following disease stages: stage 0 = no gait
Monocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis-Associated Interstitial Lung Disease.
progressive disease in patients. Monocyte expression of lipoxygenase homology domains
Single-Nucleus RNA Sequencing Reveals the Spatiotemporal Dynamics of Disease-Associated Microglia in Amyotrophic Lateral Sclerosis.
disease progressed, reaching their peak in the late disease stage
The impact of enlarged perivascular spaces on the association among peripheral inflammation, disease progression and motor symptoms in Parkinson's disease.
disease progression and motor symptoms in PD patients. METHODS: This
Blood neurofilament light chain levels are associated with disease progression in a transgenic SCA3 mouse model.
disease progression, providing an accessible disease biofluid biomarker to interrogate
Parkinson's Disease: Biomarkers for Diagnosis and Disease Progression.
disease (PD) is a progressive neurological disease that causes both
Neurexin1 level in Huntington's Disease and decreased Neurexin1 in disease progression.
disease progression. Neurexin1 (NRXN1), a synaptic cell adhesion molecule primarily
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.
disease, type C1 (NPC1) is a lysosomal storage disorder characterised by progressive
Current State and Future Directions in the Therapy of ALS.
disease progression remains challenging. Varying by country Riluzole, Edaravone, and Sodium
Microglia replacement halts the progression of microgliopathy in mice and humans.
disease progression. We then replaced CSF1R-deficient microglia in eight
Gene Therapy for Parkinson's Disease Using Midbrain Developmental Genes to Regulate Dopaminergic Neuronal Maintenance.
disease (PD) is the second most prevalent neurodegenerative disorder. It is characterized by the progressive
Neurodegeneration in multiple sclerosis.
disease progression and permanent neurologic disability. MS is a heterogeneous
Neuronal Vulnerability of the Entorhinal Cortex to Tau Pathology in Alzheimer's Disease.
disease progression. Early detection methods, such as imaging techniques and assessments
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
disease progression. The array of available rodent models is large
Allelic effects on uromodulin aggregates drive autosomal dominant tubulointerstitial kidney disease.
disease progression in ADTKD. Based on two prevalent missense UMOD
Exosome Proteomics of SOD1D90A Mutation Suggest Early Disease Mechanisms, and FN1 as a Biomarker.
disease progressed. The linear regression analysis, using ALSFRS scores of patients
Biomarkers in Spinocerebellar Ataxias.
progressive diseases. As targeted therapies for SCAs are being developed
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
disease progression during or after platinum-based chemotherapy. Phase 1 data
Transcriptome analysis identifies the role of Class I histone deacetylase in Alzheimer's disease.
disease progression but can alter the genetic expression of the brain
Association of Initial Side of Brain Atrophy With Clinical Features and Disease Progression in Patients With GRN Frontotemporal Dementia.
disease progression of FTD-GRN depends on the initial side
TDP-43 seeding activity in the olfactory mucosa of patients with amyotrophic lateral sclerosis.
disease progressed. Similarly, plasma NfL levels were higher in both
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
disease progression under appropriate conditions. However, these end points may not be practical
Empagliflozin in Patients with Chronic Kidney Disease.
progression of kidney disease (defined as end-stage kidney disease
Knockout of P2Y12 receptor facilitates neuronal envelopment by reactive microglia and accelerates prion disease.
disease progression and associated neuropathology. In healthy adult mice, deletion